Amgen antibody shows promise in myeloma trial, gets FDA fast track

Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

from Reuters: Health News https://ift.tt/2FXJWx9
via IFTTT